MLAB Overview

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is99.00 USD with a low forecast of 83.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mesa Laboratories Inc revenue for the last quarter amounts to 65.13M USD, increased 3.64

Mesa Laboratories Inc. EPS for the last quarter amounts to 0.65 USD, decreased -309.68

Mesa Laboratories Inc (MLAB) has 730 emplpoyees as of March 26 2026.

Today MLAB has the market capitalization of 448.23M USD.